LAV Biosciences Fund V, L.P. - 23 Nov 2022 Form 4 Insider Report for Terns Pharmaceuticals, Inc. (TERN)

Role
10%+ Owner
Signature
/s/ Yun Luo, as Authorized Signatory of LAV Biosciences Fund V, L.P.
Issuer symbol
TERN
Transactions as of
23 Nov 2022
Net transactions value
-$8,250,000
Form type
4
Filing time
28 Nov 2022, 15:56:54 UTC
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TERN Common Stock Sale $5,500,000 -1,000,000 -71% $5.50 405,583 23 Nov 2022 See footnotes F1, F2
transaction TERN Common Stock Sale $1,833,337 -333,334 -24% $5.50 1,059,523 23 Nov 2022 See footnotes F2, F3
transaction TERN Common Stock Sale $916,663 -166,666 -24% $5.50 529,762 23 Nov 2022 See footnotes F2, F4
holding TERN Common Stock 1,286,698 23 Nov 2022 See footnotes F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares held by LAV Biosciences Fund V, L.P.
F2 LAV Corporate GP, Ltd. is the general partner of LAV GP III, L.P., which is the general partner of the parent entity of Hopewell Resources Holdings Limited and Oriental Spring Venture Limited. LAV Corporate IV GP, Ltd., is the general partner of LAV GP IV, L.P., which is the general partner of the parent entity of LAV Aqua Limited. LAV Corporate V GP, Ltd., is the general partner of LAV GP V, L.P., which is the general partner of LAV Biosciences Fund V, L.P. Dr. Yi Shi is the managing partner of LAV Corporate GP, Ltd., LAV Corporate IV GP, Ltd., and LAV Corporate V, L.P. and has all voting and investment power with respect to shares beneficially held by each of Hopewell Resources Holdings Limited, Oriental Spring Venture Limited, LAV Aqua Limited and LAV Biosciences Fund V, L.P. Dr. Yi Shi is a managing partner at Lilly Asia Ventures.
F3 Shares held by Hopewell Resources Holdings Limited.
F4 Shares held by Oriental Spring Venture Limited.
F5 Shares held by LAV Aqua Limited.